Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
The study underscores the potential of user-owned devices in health monitoring. With a positive predictive value of 0.84, the smartwatch app could be a significant step towards large-scale, user-driven monitoring for atrial fibrillation.
Cardiology November 28th 2023
ACP Internist
The recent LODESTAR clinical trial has revealed that although the two statins are equally effective in preventing heart attacks, strokes, and death, one has been associated with a higher risk of developing type 2 diabetes and requiring cataract surgery.
Cardiology November 15th 2023
MDLinx
The tragic event involving Matthew Perry has brought to light the potential cardiovascular risks associated with hot tub use. As physicians, it’s crucial to understand these risks and educate patients accordingly, particularly those with underlying heart conditions.
All Specialties November 8th 2023
A 75-year-old man with dyspnea and exertional syncope is diagnosed with aortic stenosis. After an echocardiogram, what’s next?
Cardiology November 8th 2023
Medical News Today (MNT)
A recent study involving 4,400 participants revealed that two major statins—rosuvastatin and atorvastatin—are equally effective at reducing heart attacks, strokes, and all-cause deaths. However, it was found that the rosuvastatin group was more likely (7.2%) to develop type 2 diabetes than the atorvastatin group (5.3%).
Cardiology November 2nd 2023
British Medical Journal
This study provides valuable insights into the comparative benefits and risks of rosuvastatin and atorvastatin in adults with coronary artery disease. Notably, while both drugs showed comparable efficacy, rosuvastatin was associated with a higher risk of new onset diabetes mellitus and cataract surgery.
Cardiology October 25th 2023